Novartis AG ADR NOTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
-
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal — Update
-
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal
-
European Pharma Leaders Push for National Reforms to Boost Investment
-
Novartis to End ALS Trial Amid String of Study Failures
-
Novartis's failed trial for cholesterol drug leads to broad biopharma stock selloff
-
Novartis Down Over 12%, On Pace for Record Percent Decrease — Data Talk
-
Beneath the surface, the next stock-market leaders are getting ready to break out, says Morgan Stanley
Trading Information
- Previous Close Price
- €135.00
- Day Range
- €131.00–131.00
- 52-Week Range
- —–145.00
- Bid/Ask
- €132.00 / €136.00
- Shares Outstanding
- 1.90B
- Market Cap
- $248.99B
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 14.14
- Price/Sales
- 5.00
- Dividend Yield (Trailing)
- 3.07%
- Dividend Yield (Forward)
- 3.07%
- Dividend Payment Schedule
- Mar
- Total Yield
- 5.36%
Company Profile
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 75,267
- Website
- https://www.novartis.com
Competitors
Valuation
|
Metric
|
NOTA
|
GSK
|
JNJ
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.14 | 11.40 | 22.89 |
Price/Book Value | 6.58 | 3.96 | 7.05 |
Price/Sales | 5.00 | 2.12 | 6.08 |
Price/Cash Flow | 14.76 | 9.07 | 21.22 |
Price/Earnings
NOTA
GSK
JNJ
Financial Strength
|
Metric
|
NOTA
|
GSK
|
JNJ
|
|---|---|---|---|
Quick Ratio | 0.55 | 0.52 | 0.73 |
Current Ratio | 0.86 | 0.82 | 1.09 |
Interest Coverage | 11.90 | 9.51 | 25.00 |
Quick Ratio
NOTA
GSK
JNJ
Profitability
|
Metric
|
NOTA
|
GSK
|
JNJ
|
|---|---|---|---|
Return on Assets (Normalized) | 14.74% | 11.66% | — |
Return on Equity (Normalized) | 39.06% | 42.98% | — |
Return on Invested Capital (Normalized) | 21.25% | 22.63% | — |
Return on Assets
NOTA
GSK
JNJ
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|LVKJBn^ | LOCK|VXb | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|k<HTsJ< | LOCK|zV | $610B | |||
| AbbVie Inc
ABBV
| LOCK|<M<XkMz | LOCK|<#C | $501B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|wGJ?WBqk | LOCK|Qxk | $365B | |||
| Merck & Co Inc
MRK
| LOCK|wd?>W% | LOCK|pc | $358B | |||
| Novartis AG ADR
NVS
| LOCK|%vzY$>? | LOCK|^y? | $288B | |||
| AstraZeneca PLC
AZN
| LOCK|pCVkxr!W | LOCK|h^ | $261B | |||
| Amgen Inc
AMGN
| LOCK|zv?kZCrS | LOCK|%@@ | $235B | |||
| Gilead Sciences Inc
GILD
| LOCK|$#%L^g | LOCK|y! | $195B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|RP%zz<l | LOCK|J< | $174B |
United States